Access to Medications for Opioid Use Disorder in U.S. Jails and Prisons

THIS 50 STATE SNAPSHOT presents current laws, policies, and court actions related to access to medications for opioid use disorder (MOUD) in correctional facilities in the U.S as of April 2021. Where available, this survey also includes examples of programs that are county- or facility-specific.

This report focuses specifically on three categories of medications approved by the U.S. Food and Drug Administration to treat opioid use disorder (OUD): methadone, buprenorphine and naltrexone, but also mentions branded versions of these medications, which include combination medications, long-acting versions, and medications with different methods of administration (for example, injectable or oral). Individuals leaving jails and prisons are between 10 and 40 times more likely to die of an opioid overdose than the general population—making them one of the highest at-risk groups for opioid overdose. This risk is especially acute three to four weeks post-release. Access to MOUD in jails and prisons is one targeted approach that can help decrease risk for overdose death.